Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Attention Turns To Celgene's Other Pipeline Prospects Following Second Positive Luspatercept Read-Out

Executive Summary

Celgene and Acceleron's novel erythroid maturation agent, luspatercept, has reported positive Phase III results in a second potential indication, beta-thalassemia, and approval filings are confirmed for the first half of 2019.

You may also be interested in...



Key Drug Launches To Plan For In 2019

Around three dozen key late-stage products could reach their first markets in 2019, according to a recent report from Informa Pharma's Biomedtracker. Company execs may need to plan for the disruptive potential of this group of new medicines on established markets and standards of care.

Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications

Second quarter Otezla sales came in slightly lower than consensus, but Celgene believes changes in inventory levels will smooth out for the remainder of 2018. However, the company is reconsidering its pursuit of IBD indications for Otezla in deference to its potential blockbuster ozanimod.

Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie

With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC123386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel